Valuation: Control Bionics Limited

Market Cap 30.49M 21.85M 18.75M 17.6M 16.08M 30.34M 2.08B 208M 80.72M 1.05B 82.03M 80.25M 3.48B P/E 2024
-1.4x
P/E 2025 -1.3x
Enterprise Value 30.25M 21.68M 18.61M 17.46M 15.95M 30.1M 2.07B 207M 80.1M 1.04B 81.4M 79.63M 3.45B EV / Sales 2024
1.92x
EV / Sales 2025 1.4x
Free-Float
73.48%
Yield 2024 *
-
Yield 2025 -
1 day+3.39%
1 week+1.67%
Current month-4.69%
1 month-10.29%
3 months+1.67%
6 months+8.93%
1 week 0.06
Extreme 0.057
0.06
1 month 0.06
Extreme 0.056
0.07
Current year 0.05
Extreme 0.05
0.1
1 year 0.03
Extreme 0.032
0.1
3 years 0.03
Extreme 0.026
0.1
5 years 0.03
Extreme 0.026
0.73
10 years 0.03
Extreme 0.026
1.24
Manager TitleAgeSince
Chief Executive Officer - 19/01/2023
Director of Finance/CFO - 13/05/2024
Chief Tech/Sci/R&D Officer - 01/01/2014
Director TitleAgeSince
Chairman 66 19/11/2025
Director/Board Member - 19/01/2023
Director/Board Member - 01/04/2023
Change 5-day change 1-year change 3-year change Capi.($)
+3.39%+1.67%+52.50%-20.78% 18.8M
-0.85%+4.13%+24.19%-30.71% 17.8B
+15.78%+0.07%-30.47%+110.64% 1.73B
-1.06%+7.46%-46.88%-80.80% 1.03B
-0.99%-2.68%-25.04%+20.91% 962M
-0.03%+0.22%+64.01%-5.52% 780M
+2.67%+1.05%-38.28%-44.75% 689M
+3.43%-8.53%-44.27%-48.79% 563M
-1.35%+0.41%-40.37%-37.42% 459M
-5.18%+1.51%+63.19%+42.98% 455M
Average +1.63%+3.13%-2.14%-9.42% 2.45B
Weighted average by Cap. +0.42%+6.75%+12.88%-19.58%

Financials

2024 2025
Net sales 5.35M 3.83M 3.29M 3.09M 2.82M 5.33M 366M 36.56M 14.17M 185M 14.4M 14.09M 611M 6.14M 4.4M 3.78M 3.55M 3.24M 6.12M 420M 41.99M 16.27M 212M 16.54M 16.18M 702M
Net income -5.91M -4.24M -3.64M -3.41M -3.12M -5.89M -404M -40.41M -15.66M -204M -15.91M -15.57M -675M -6.11M -4.38M -3.76M -3.53M -3.22M -6.08M -418M -41.74M -16.18M -211M -16.44M -16.08M -698M
Net Debt -96.95K -69.48K -59.64K -55.97K -51.12K -96.48K -6.63M -662K -257K -3.34M -261K -255K -11.07M -237K -170K -146K -137K -125K -236K -16.22M -1.62M -628K -8.18M -638K -625K -27.1M
Logo Control Bionics Limited
Control Bionics Limited is a medical device company assisting patients whose ability to communicate verbally or via text and social media is compromised by illnesses, such as Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Its products include Control Bionics Trilogy Systems, NeuroStrip, NeuroNode, Cosmos Connect and accessories. NeuroNode technology is a wireless wearable device that detects minute signals sent from the brain to any skeletal muscle and is captured as electromyography output. This output is then sent wirelessly via NeuroNode to a personal computer, enabling speech and other computer-controlled functions like email and texting. Its technology is integrated with eye gaze technology whereby the eye gaze enables a cursor to be moved about a computer screen, driven much like a mouse and the NeuroNode acts like a mouse button. It is commercializing its advancement in its technology, NeuroStrip. It is focused on neuromuscular rehabilitation and athletic optimization.
Employees
-
Date Price Change Volume
26/08/26 A$0.0610 +3.39% 145,482
25/08/26 A$0.0590 +1.72% 491,456
24/08/26 A$0.0580 -3.33% 296,570
21/08/26 A$0.0600 0.00% 704,803
20/08/26 A$0.0600 0.00% 1,810,561

Annual profits - Rate of surprise